

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

SECTION 1. IDENTIFICATION

Product name : Human Gonadotropin Chorionic / Serum Gonadotropin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 37 McCarville Street
Charlottetown, PE C1E 2A7
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1A
Specific target organ toxicity : Category 1 (Ovary)
- repeated exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Ovary) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Gonadotropin, pregnant mare serum	No data available	9002-70-4*	>= 1 - <= 5	TSC
Gonadotropin, chorionic	No data available	9002-61-3*	>= 0.5 - <= 1.5	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : May damage fertility. Suspected of damaging the unborn child.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/21/2026
8.0	05/09/2026	636528-00025	Date of first issue: 05/03/2016

delayed	Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Sulfur oxides Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Gonadotropin, pregnant mare serum	9002-70-4	TWA	4 µg/m ³ (OEB 4)	Internal
		Wipe limit	40 µg/100 cm ²	Internal
Gonadotropin, chorionic	9002-61-3	TWA	OEB 4 (3 µg/m ³)	Internal
		Wipe limit	25 µg/100 cm ²	Internal

Engineering measures : Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!
For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Appearance	:	powder
Color	:	white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Acute oral toxicity : LD50 (Mouse): 120 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): > 1,700 mg/kg
Application Route: Intravenous

LD50 (Mouse): > 1,700 mg/kg
Application Route: Subcutaneous

LD50 (Rat): 500 mg/kg
Application Route: Intravenous

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

LD50 (Rat): 500 mg/kg
Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Genotoxicity in vivo : Test Type: Cytogenetic assay
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive
Remarks: Not classified due to data which are conclusive although insufficient for classification.

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Components:

Gonadotropin, pregnant mare serum:

Carcinogenicity - Assessment : No data available

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Gonadotropin, pregnant mare serum:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: LOAEL: 10 µg/kg
Result: Effects on fertility.
Remarks: May cause adverse reproductive effects.
Based on data from similar materials

Effects on fetal development : Remarks: May cause birth defects.
Based on data from similar materials

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

Gonadotropin, chorionic:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Intravenous injection
Fertility: LOAEL: 8.89 mg/kg body weight
Result: Effects on fertility.

Test Type: Fertility
Application Route: Intraperitoneal injection
Fertility: LOAEL: 0.883 mg/kg body weight
Result: Effects on fertility.

Test Type: Fertility
Species: Monkey
Fertility: LOAEL: 0.224 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Hamster
Application Route: Intraperitoneal injection
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight
Result: Embryo-fetal toxicity.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on sexual function and

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

Assessment fertility from human epidemiological studies., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Ovary) through prolonged or repeated exposure.

Components:

Gonadotropin, chorionic:

Target Organs : Ovary
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Gonadotropin, pregnant mare serum:

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 3 Days
Symptoms : No adverse effects.

Species : Rat
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Reproductive organs

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gonadotropin, pregnant mare serum:

Inhalation : Symptoms: Headache, Fatigue, mood swings, altered mental status, Edema, Allergic reactions, Effects on fertility.
Skin contact : Remarks: May produce an allergic reaction.
Ingestion : Remarks: May be harmful if swallowed.

Gonadotropin, chorionic:

Inhalation : Target Organs: ovaries
Symptoms: effects on menstruation, gynecomastia, Headache, mental depression, Irritability, restlessness, Fatigue

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.0 Revision Date: 05/09/2026 SDS Number: 636528-00025 Date of last issue: 01/21/2026
Date of first issue: 05/03/2016

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Endocrine disrupting properties

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/21/2026
8.0	05/09/2026	636528-00025	Date of first issue: 05/03/2016

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

CN IECSC : not determined

Canadian lists

No substances are subject to CEPA Section 84 Ministerial Conditions.

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/21/2026
8.0	05/09/2026	636528-00025	Date of first issue: 05/03/2016

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8